As students head back to school this week, boys, as well as girls, will have funded access to the HPV […]
Continue readingpharmac
Keytruda decision hasn’t addressed drug-funding problems – Expert reaction
New Zealand has one of the highest rates of melanoma in the world but lags in funding novel drugs that […]
Continue readingPharmac confirms funding for melanoma drug – In the News
Drug-buying agency Pharmac officially announced funding for the melanoma treatment Keytruda on Tuesday. It followed a provisional decision in June […]
Continue readingPHARMAC needs funding boost – Dr Francis Hunter
Writing on Stuff.co.nz* the University of Auckland’s Dr Francis Hunter outlines the situation PHARMAC and the Government face over the […]
Continue readingPush for Keytruda funding – Expert reaction
Public pressure is growing for the Government to fund the melanoma drug Keytruda, listed as ‘low priority’ by drug funding […]
Continue readingTransparency needed in cancer drug markets – Expert reaction
Experts are calling for greater transparency and fairness in cancer drug pricing, in light of findings revealing discrepancies between Europe, […]
Continue readingPHARMAC not to fund melanoma drug – In the News
PHARMAC’s decision not to fund melanoma treatment pembrolizumab – marketed as Keytruda – has been widely covered in the media. Public […]
Continue readingNew melanoma drug in the headlines
A promising melanoma drug has doctors and patient groups calling for the medicine to be funded by PHARMAC in New […]
Continue readingTrade deals and healthcare – Prof John McMillan
On the university of Otago Bioethics Centre blog, centre Director Prof John McMillan writes about the leaked details of the […]
Continue readingUPDATED: Funding new medicines in NZ – Expert reaction
Funding new medicines in New Zealand can take over eight years and recommending a drug as high priority does not […]
Continue reading